


Listing of Claims:


1. (Previously Presented) A method for improving memory performance in an animal, the method comprising:

administering a therapeutically effective dose of a derivative of a succinate ester of general formula (I), or a stereo-isomer or a pharmaceutically acceptable salt thereof:




wherein,

R₁ and R₄ are selected from -OCH₃, -OH, -O-Glu,




R₂ and R₃ are selected from H, -OH, -O-Glu,



R₅ is selected from non-branched or branched C₁₋₆ alkyls; and




the configuration of chiral center at C-2 and C-3 are 2R3S, 2R3R, 2S3S and 2S3R respectively.

2. (Previously Presented) The method according to claim 1, characterized in that said compound of formula (I) is:








or a stereo-isomer or a pharmaceutically acceptable salt thereof, wherein R₅ is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl; and R₁, R₂, R₃, and R₄ are the same as that in claim 1.






3. (Previously Presented) The method according to claim 2 characterized in that said compounds include:



Response to Office Action Mailed June 27, 2008



1,4-bis(β-D-glucopyranosyloxybenzyl)-2-β-D-glucopyranosyl-2-isobutylmalate (dactylorhin A)
(W8);



and stereo-isomers and pharmaceutically acceptable salts thereof.

4. (Previously Presented) The method according to claim 1, wherein the compound is a pharmaceutically acceptable salt.

5. (Previously Presented) The method according to claim 1, wherein the animal has Alzheimer's disease, vascular dementia, or a learning or memory obstacle.

6. (Canceled).

7. (Canceled).

8. (Previously Presented) A method for improving memory performance in an animal comprising:

administering a therapeutically effective dose of an extract of *Coeloglossum viride* (L.) Hartm. var. *bracteatum* (Willd.) Richter, said extract comprising ethanol soluble compounds.

9. (Previously Presented) The method according to claim 8, wherein the animal has Alzheimer's disease, vascular dementia, or a learning or memory obstacle.

10. (Canceled).

11. (Canceled).

12. (Previously Presented) The method according to claim 2, wherein the compound is a pharmaceutically acceptable salt.

13. (Previously Presented) The method according to claim 3, wherein the compound is a pharmaceutically acceptable salt.

14. (Canceled).

15. (Canceled).

16. (Canceled).

17. (Previously Presented) The method of claim 8, wherein the extract is prepared from rhizomes.

18. (Previously Presented) The method of claim 8, wherein the animal is a human.

19. (Previously Presented) The method of claim 18, wherein the human has Alzheimer's disease.

20. (Previously Presented) The method of claim 8, further comprising administering at least one of: scopolamine, cycloheximide, and amyloid-beta peptides.